Adagene (ADAG) Receivables - Net (2019 - 2026)
Adagene (ADAG) posted quarterly Receivables - Net of $3.0 million for Q4 2021, up 384.51% quarter-over-quarter from $619185.0 in Q2 2021.
Powered by 
Analysis
Adagene (ADAG) Receivables - Net (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Receivables - Net for 2 consecutive years, with $3.0 million the latest figure, recorded in Q4 2021.
- In Q4 2021, Receivables - Net changed N/A year-over-year to $3.0 million; the TTM figure through Dec 2021 stood at $3.0 million (changed N/A YoY), while the FY2021 annual figure was $3.0 million, changed N/A from the prior year.
- Receivables - Net advanced to $3.0 million in Q4 2021 per ADAG's latest filing, from $619185.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $3.0 million in Q4 2021 and bottomed at $480000.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | Adagene | 213.60 Mn | 213.60 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 150,000.00 |
| Dec 31, 2021 | 3.00 Mn |
| Jun 30, 2021 | 619,185.00 |
| Dec 31, 2019 | 480,000.00 |